micro-community-banner
Profile Image
  • Saved
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling - PubMed

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37047815/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Conclusions: Our study reveals the adverse effects of metabolic disorder- and obesity-induced epicardial fat impairing cardiomyocyte H9c2 function by disturbing the mitochondrial function, such as reducing membrane potential, ROS accumulation, Ca2+ overload, and associated regulator expression. However, most of the dysregulation was...

Profile Image
  • Saved
New insights into the treatment of obesity - PubMed

New insights into the treatment of obesity - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37055715/

Obesity is a chronic, progressive, and relapsing disease with a rising global prevalence associated with increased morbidity and mortality and reduced quality of life. Treatment of obesity requires a comprehensive...

Conclusions/Relevance: these novel agents promise to narrow the gap between the weight-loss effects of behavior interventions, previous pharmacotherapies, and bariatric surgery. In this narrative review, we highlight established and emerging therapeutic treatments for long-term obesity management and position them in a framework according to...

Profile Image
  • Saved
The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials - PubMed

The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37055712/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Conclusions: Semaglutide 2.4 mg was associated with improvement in health utility scores compared with placebo, reaching statistical significance in STEP 1, 2 and 4.

Profile Image
  • Saved
Diagnosing obesity in your patients

Despite its increasing prevalence, obesity is one of the most misunderstood conditions in medicine. In fact, the AMA didn’t recognize it as a disease until 2013! In the United States, there are an estimated 30 million adults with diabetes, and 100 million adults with obesity. Obesity increases health risks and is associated with more than 60 comorbidities.

Physicians are key to the diagnosis of obesity, nevertheless studies show that only 55% of patients with obesity who seek treatment are diagnosed with this condition. Two key criteria for diagnosis include BMI ≥ 30 and sex-specific waist circumference (>40 inches in men; >35 inches in women).

When assessing waist circumference, be sure to take the following steps:

  1. Place the tape measure horizontally around the patient’s waist (i.e., between the lowest rib and the top of the hip bone); the umbilicus (i.e., belly button); or at the narrowest point of the midsection.
  2. Maintain a snug fit around the patient’s waist without pressing the skin and have the patient take a deep breath and exhale.
  3. Measure the waist circumference on exhalation.

Which of your patients do you evaluate for obesity? What measures do you use to diagnose obesity, and who takes these measures?

Profile Image

Show More Comments

  • Saved
Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice

Source : https://www.frontiersin.org/articles/10.3389/fendo.2023.1095432/full

Background and objectivesObesity is a global health problem with few pharmacologic options. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue that induces weight loss. Yet, the role of semaglutide in adipose...

Conclusion: Semaglutide can effectively reduce visceral fat and blood lipids and improve glucose metabolism in obese mice. Semaglutide treatment might have beneficial effects on adipose tissues through the regulation of lipid uptake, lipid storage, and lipolysis in white adipose tissue.

Profile Image